arrow
F

Francesco Pantano

university campus bio-medico
H指数:36
被引数:5,503

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Chemotherapy Backbone and Outcomes of Immune Checkpoint Inhibitor Combinations Across Solid Tumors: A Pan-Tumor Network Meta-Analysis

化疗基础方案与免疫检查点抑制剂联合疗法在实体瘤中的疗效:一项泛肿瘤网络Meta分析

2026-09-170
OAAI
Broad baseline-variable profiling of visceral conversion in bone-only HR+/ HER2-metastatic breast cancer treated with CDK4/6 inhibitors

骨转移性HR+/HER2-转移性乳腺癌经CDK4/6抑制剂治疗后腹腔转化的大范围基线-变量分析

2026-09-011
OA
Skeletal metastatic burden as a strong prognostic factor of survival in advanced NSCLC treated with chemo-immunotherapy: An exploratory imaging-based analysis

骨转移负荷作为接受化疗-免疫治疗晚期非小细胞肺癌生存的强预后因素:一项基于影像学的探索性分析

2026-08-010
OAAI
Family history enrichment in Non-Small cell Lung Cancer: A cross-sectional − prospective study to inform referral for germline testing

非小细胞肺癌中的家族史信息补充:一项用于指导胚系检测转诊的横断面-前瞻性研究

2026-02-260
OAAI
Breast CancerTrastuzumab-deruxtecan and radiotherapy: a safety sub-analysis of combart prospective cohort study

乳腺癌:曲妥珠单抗-德鲁克特肯与放射治疗:COMBART前瞻性队列研究的 safety 子分析

2025-09-010
OAAI
Dose dependent detrimental effect of baseline pantoprazole on clinical outcomes from first-line chemo-ICI regimens in patients with advanced stage NSCLC

基线泮托拉唑对晚期NSCLC患者一线化疗联合免疫检查点抑制剂方案临床结局的剂量依赖性有害影响

2024-09-010
PRE
Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis

Sacituzumab Govitecan治疗晚期三阴性乳腺癌患者的多中心真实世界分析

2024-03-2626
OAAI
MiR-662 is associated with metastatic relapse in early-stage breast cancer and promotes metastasis by stimulating cancer cell stemness

MiR-662与早期乳腺癌的转移复发有关,并通过刺激癌细胞的干细胞来促进转移

2023-07-131
OAAI
Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: An exploratory analysis

接受免疫检查点抑制剂治疗的无骨转移患者骨转换标志物的变化: 一项探索性分析

2022-12-0115
OAAI